Cholesterol and Coronary Heart Disease: Future Directions

JAMA: The Journal of the American Medical Association

Volumn 264, Issue 23, 1990, Pages 3053-3059

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FATTY ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PROBUCOL; TRIACYLGLYCEROL;

AGED; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIET; HIGH RISK POPULATION; HYPERCHOLESTEROLEMIA; OBESITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGED; CHOLESTEROL; CORONARY DISEASE; DIETARY FATS; FORECASTING; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL CHOLESTEROL; MALE; MIDDLE AGE; RISK FACTORS; TRIGLYCERIDES;

EID: 0025597966     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1990.03450230089035     Document Type: Article

References (81)

1. Lenfant C. A new challenge for America: the National Cholesterol Education Program. Circulation. 1986;73:855-856.
2. Grundy SM, Bilheimer D, Blackburn H, et al. Rationale of the diet-heart statement of the American Heart Association: report of Nutrition Committee. Circulation. 1982;65:839A-854A.
3. Stamler J, Wentworth D, Neaton J. Is the relationship between serum cholesterol and risk of death from CHD continuous and graded? JAMA. 1986;256:2823-2828.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
6. Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
7. Malenka DJ, Baron JA. Cholesterol and coronary heart disease: the importance of patient-specific attributable risk. Arch Intern Med. 1988; 148:2247-2252.
8. Gordon DJ, Rifkind BM. Treating high blood cholesterol in the older patient. Am J Cardiol. 1989;63:48H-52H.
9. Denke MA, Grundy SM. Hypercholesterolemia in the elderly: resolving the treatment dilemma. Ann Intern Med. 1990;112:780-792.
10. The Lipid Research Clinics Population Studies Data Book. Bethesda, Md: National Institutes of Health; 1980;1. Publication 80-1527.
11. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J. 1987;114:1467-1503.
12. Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effects of estrogen on low-density lipoprotein metabolism in males: short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest. 1989;84:802 810.
13. Crouse JR III. Gender, lipoproteins, diet and cardiovascular risk: sauce for the goose may not be sauce for the gander. Lancet. 1989;1:318-320.
14. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256: 2835-2838.
15. McGill HC Jr. Fatty streaks in the coronary arteries and aorta. J Lab Invest. 1968;18:560-564.
16. Phillips NR, Havel RJ, Kane JP. Levels and irrelationships of serum and lipoprotein cholesterol and triglycerides: association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Arteriosclerosis. 1981;1:13-34.
17. Myers LH, Phillips NR, Havel RJ. Mathematical evaluation of methods for estimation of the concentration of the major lipid components of human serum lipoproteins. J Lab Clin Med. 1976;88:491-505.
18. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986;112:432-437.
19. Guianturco SH, Bradley WA. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. Semin Thromb Hemost. 1988; 14:165-169.
20. Richards EG, Grundy SM, Cooper K. Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol. 1989;63:1214-1220.
21. Mitropoulos KA. Hypercoagulability and factor VII in hypertriglyceridemia. Semin Thromb. Hemost. 1988;14:246-252.
22. Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657-663.
23. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
24. Wissler RW, Vesselinovitch D. The development and use of animal models in atherosclerosis research. In: Gallo LL, ed. Molecular and Cellular Mechanisms, Prevention and Treatment. New York, NY: Plenum Press; 1987:337-357.
25. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
26. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
27. Report of the Committee of Principal Investigators. World Health Organization Clofibrate Trial: a cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J. 1978;40:1069-1118.
28. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives in the Framingham Study. Ann Intern Med. 1979;90:85-91.
29. Gordon DJ, Probstfeld JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American series. Circulation. 1989;79:8-15.
30. van Tol A. Reverse cholesterol transport. In: Steinmetz A, Kaffarnik H, Schneider J, eds. Cholesterol Transport Systems and Their Relation to Atherosclerosis. New York, NY: Springer-Verlag NY Inc; 1989:85-91.
31. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low-density lipoprotein aggregation by high-density lipoprotein or apolipoprotein.I-A. J Lipid Res. 1990;31:645-658.
32. Grundy SM, Goodman DEW, Rifkindkind BM, Cleeman JI. The place of HDL in cholesterol management: a perspective from the National Cholesterol Education Program. Arch Intern Med. 1989;149:505-510.
33. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 1988;148:36-69.
34. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoliprotein B and A-1 and coronary artery disease in humans. Arteriosclerosis. 1984;4:79-83.
35. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med. 1989;320:915-923.
36. Fogelman AM, Schecter JS, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low-density lipoprotein leads to cholesterol accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980;77:2214-2218.
37. Keys A. Coronary heart disease in seven countries. Circulation. 1970;41(suppl 1):I-1-I-211.
38. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
39. Grundy SM, Vega GL. Causes of high blood cholesterol. Circulation. 1990;81:412-427.
40. Vega GL, Grundy SM. In vivo evidence for reduced binding of low-density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest. 1986;78:1410-1414.
41. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low-density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987;84:6919-6923.
42. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A. 1989;86:587-591.
43. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis. 1987;7:203-207.
44. Bonanome A, Grundy SM. Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. N Engl J Med. 1988;318:1244-1248.
45. Hashim SA, Arteaga A, van Itallie TB. Effect of a saturated medium-chain triglyceride on serumlipids in man. Lancet. 1960;1:1105-1108.
46. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr. 1965;17:281-295.
47. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323:439-445.
48. Grundy SM, Barrett-Connor E, Rudel LL, Miettinen T, Spector AA. Workshop on the impact of dietary cholesterol on plasma lipoproteins and atherogenesis. Arteriosclerosis. 1988;8:95-100.
49. Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease: the epidemiological evidence. Arch Pathol Lab Med. 1988;112:1032-1040.
50. Ashley FW Jr, Kannel WB. Relation of weight change to changes in atherogenic traits: the Framingham Study. J Chronic Dis. 1974;27:103-114.
51. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism. 1980;29:1053-1060.
52. Stamler J. Overweight, hypertension, hypercholesterolemia, and coronary heart disease. In: Mananni M, Lewis B, Contaldo F, eds. Medical Complications of Obesity. Orlando, Fla: Academic Press Inc; 1979:191-216.
53. Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res. 1985;26:194-202.
54. Mensink RP, Katan MB. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. N Engl J Med. 1989;321:436-441.
55. Dreon DM, Vranizan KM, Krauss RM, Austin MA, Wood PD. The effects of polyunsaturated fat vs monounsaturated fat on plasma lipoproteins. JAMA. 1990;263:2462-2466.
56. Weyman C, Berlin J, Smith AD, Thompson RSH. Linoleic acid as an immunosuppressive agent. Lancet. 1975;2:33-34.
57. Reddy BS. Amount and type of dietary fat and colon cancer: animal model studies. Prog Clin Biol Res. 1986;222:295-309.
58. Sturdevant RAL, Pearce ML, Dayton S. Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med. 1973;288:24-27.
59. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of dietary polyunsaturated and saturated fat on the properties of high-density lipoprotein and the metabolism of apolipoprotein A-I. J Clin Invest. 1978;61:1582-1592.
60. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL. Low-density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci U S A. 1990;87:3894-3898.
61. Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. N Engl J Med. 1986;314:745-748.
62. Committee on Diet and Health Food and Nutrition Board, Commission on Life Sciences, National Research Council. Diet and Health: Implications for Reducing Chronic Disease Risk. Washington, DC: National Academy Press; 1989.
63. American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus, 1986. Diabetes Care. 1987;10:126-132.
64. Mensink RP, Katan MB. Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet. 1987;1:122-125.
65. Ginsberg HN, Barr SL, Gilbert BA, et al. Reduction of plasma cholesterol levels in normal men on an American Heart Association step 1 diet or a step 1 diet with added monounsaturated fat. N Engl J Med. 1990;322:574-579.
66. Wilson PWF, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. JAMA. 1989;262:41-44.
67. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33.
68. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol. 1990;65:23F-26F.
69. Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA. 1984;251: 2241-2246.
70. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
71. Parthasarathy S, Young S, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low-density lipoprotein. J Clin Invest. 1986;77:641-644.
72. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987;84:5928-5931.
73. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986;57:29H-35H.
74. Jialal I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit the oxidative modification of low-density lipoprotein. Atherosclerosis. 1990;82:185-191.
75. Blankenhorn DM, Nessim SA, Johnson RL, Sanmarco ME, Azen SP. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
76. Brown BG, Lin JT, Schaefer SM, Kaplan CA, Dodge HT, Albers JJ. Niacin or lovastatin, combined with colestipol regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoprotein B. Circulation. 1989;80(suppl II):II-266.
77. Kane JP, Mallow MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
78. Cashin-Hemphill L, Mack WJ, Pogoda J, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264:3013-3017.
79. Sempos C, Fulwood R, Haines C, Carroll M, Anda R, Williamson PF, Cleeman J. The prevalence of high blood cholesterol levels among adults in the United States. JAMA. 1989;262:45-52.
80. Palumbo PJ. Cholesterol lowering for all: a closer look. JAMA. 1989;262:91-92.
81. American Heart Association Task Force on Cholesterol Issues. The cholesterol facts: a summary of the evidence relating to dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation. 1990;81:5.